Jennifer Buell, Agenus president and COO (PR News Wire)
May 18, 2021 07:30 AM EDT
Deals

Bris­tol My­ers bets big on an­ti-TIG­IT bis­pe­cif­ic from Agenus in a part­ner­ship worth $1.5B+

Max Gelman

Senior Editor

The race to de­vel­op an­ti-TIG­IT drugs con­tin­ues to heat up, as a ma­jor I/O play­er part­ners with a biotech once rid­dled with set­backs.

Bris­tol My­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times